On July 28, 2026, Salt Lake City telehealth platform Shed announced a "sex health" vertical: five prescription treatments delivered through its existing online-evaluation-and-ship model. Three are for men — Rise, Extend and Steady — and two are for women, Desire and Euphoria. It is the same company that in June and July signed distribution and fulfillment arrangements with Australian pharma LTR Pharma for ROXUS, its intranasal ED spray, and it is best known as a compounded GLP-1 weight-loss seller.

Why It Matters

This is what the male-sexual-health category looks like after Hims proved the model and the FTC started auditing it. Two days before Shed's announcement, the FTC — joined by Utah and California — sued Hims & Hers over health-data sharing and subscription practices. The lesson the market appears to have taken is not "slow down" but "diversify the funnel": bolt sexual health onto a GLP-1 customer list, because acquisition cost is the whole game and a weight-loss patient is already in the system. The regulatory exposure is the story to watch. Compounded combination products for sexual dysfunction sit in the same gray zone that has drawn FDA warning letters and state pharmacy-board scrutiny in the compounded-GLP-1 and peptide markets. Bremelanotide and apomorphine are real drugs with real side-effect profiles — nausea, hypotension, syncope — and delivering them through asynchronous intake forms with no synchronous consult is precisely the practice pattern the FTC's Hims complaint put under a microscope. For investors, this launch is a clean case study in how fast a DTC telehealth platform can add a category; for regulators, it's a clean case study in why they might want to look.

Per Shed's own product pages, the formulations are notably polypharmaceutical. Rise is described as a triple-action ED tablet combining apomorphine, tadalafil and vardenafil. Extend, for premature ejaculation, combines paroxetine, tadalafil and L-theanine. Steady is a conventional daily tadalafil 5mg. On the women's side, Desire is a sublingual tablet combining oxytocin and bremelanotide, and Euphoria is a topical arousal cream listing L-arginine, oxytocin and niacin. Shed lists Rise from $66.33/month. Everything is prescribed after an asynchronous online evaluation by a licensed provider and shipped in plain packaging. "Sexual wellness is an essential part of overall health, yet it's an area where many people continue to struggle in silence," said CEO Morley Baker in the announcement.

Read the ingredient lists closely and the strategic logic becomes clear: these are compounded combination products, not FDA-approved branded drugs. That is the entire business model of the 2020s telehealth boom — a compounding pharmacy can produce a personalized multi-ingredient formulation that no manufacturer sells off the shelf, which conveniently sidesteps generic price competition and creates a proprietary-feeling product out of commodity molecules. Stacking two PDE5 inhibitors plus a dopamine agonist in one tablet is aggressive; bremelanotide (the active in Vyleesi, approved for hypoactive sexual desire disorder in premenopausal women) delivered sublingually alongside oxytocin is well outside its approved route and label.

Shed frames the launch as an extension of "treating the whole person," cross-selling sexual health to a base it says exceeds 150,000 members acquired mostly through weight management, longevity and hormone products.

Sources

Update — 2026-07-31

{Initial entry — story first created.}